These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 23001712)
21. Regression stage senile plaques in the natural course of Alzheimer's disease. Oide T; Kinoshita T; Arima K Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888 [TBL] [Abstract][Full Text] [Related]
22. The role of inflammation in Alzheimer's disease. Tuppo EE; Arias HR Int J Biochem Cell Biol; 2005 Feb; 37(2):289-305. PubMed ID: 15474976 [TBL] [Abstract][Full Text] [Related]
23. A review: inflammatory process in Alzheimer's disease, role of cytokines. Rubio-Perez JM; Morillas-Ruiz JM ScientificWorldJournal; 2012; 2012():756357. PubMed ID: 22566778 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Geylis V; Steinitz M Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209 [TBL] [Abstract][Full Text] [Related]
30. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Gasparini L; Ongini E; Wilcock D; Morgan D Brain Res Brain Res Rev; 2005 Apr; 48(2):400-8. PubMed ID: 15850679 [TBL] [Abstract][Full Text] [Related]
31. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. Eikelenboom P; van Gool WA J Neural Transm (Vienna); 2004 Mar; 111(3):281-94. PubMed ID: 14991455 [TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy of Alzheimer's disease: current and future trends. Geldenhuys WJ; Darvesh AS Expert Rev Neurother; 2015 Jan; 15(1):3-5. PubMed ID: 25481975 [TBL] [Abstract][Full Text] [Related]
34. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Karl T; Cheng D; Garner B; Arnold JC Expert Opin Ther Targets; 2012 Apr; 16(4):407-20. PubMed ID: 22448595 [TBL] [Abstract][Full Text] [Related]
35. Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies. Liu YH; Zeng F; Wang YR; Zhou HD; Giunta B; Tan J; Wang YJ Drug Discov Today; 2013 Dec; 18(23-24):1212-20. PubMed ID: 23954180 [TBL] [Abstract][Full Text] [Related]
36. Inflammation, immunity, and Alzheimer's disease. Town T CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):129-31. PubMed ID: 20205648 [TBL] [Abstract][Full Text] [Related]
37. Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer's Disease Clinical Phenotypes? A Clinico-Pathological Perspective. Taipa R; Sousa AL; Melo Pires M; Sousa N J Alzheimers Dis; 2016 May; 53(2):403-17. PubMed ID: 27176075 [TBL] [Abstract][Full Text] [Related]
38. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? Trepanier CH; Milgram NW J Alzheimers Dis; 2010; 21(4):1089-99. PubMed ID: 21504126 [TBL] [Abstract][Full Text] [Related]
39. Neuroinflammation in Alzheimer's disease wanes with age. Hoozemans JJ; Rozemuller AJ; van Haastert ES; Eikelenboom P; van Gool WA J Neuroinflammation; 2011 Dec; 8():171. PubMed ID: 22152162 [TBL] [Abstract][Full Text] [Related]
40. Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. Katsel P; Haroutunian V Dialogues Clin Neurosci; 2019 Mar; 21(1):7-19. PubMed ID: 31607776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]